Our annual INVEST conference, where investors and startups meet, kicks off today as a virtual event. Chris Coburn, chief innovation officer of Mass General Brigham, is a featured speaker and startups in the area of health services will present in the first track of our INVEST Pitch Perfect contest.
Cleveland Clinic’s corporate venture arm is turning to its general manager of IT commercialization to fill the role of departing Executive Director Chris Coburn–at least temporarily. The Clinic said today that Gary Fingerhut will head Cleveland Clinic Innovations as interim executive director when Coburn leaves at the end of May to begin a similar position […]
The success of Cleveland Clinic Innovations has triggered a puzzling dilemma for the world-renowned health system: how to manage the windfall of its leader. Innovations’ Executive Director Chris Coburn gets 3 percent from the sale of spinoff companies, according to several sources familiar with Coburn’s contract – including one who has personally reviewed Coburn’s deal. […]
Cleveland Clinic Innovations has reached a deal to help a Maryland health system develop and commercialize medical inventions by the health system's clinicians.
Chris Coburn is the captain of Cleveland Clinic Innovations, the corporate venturing arm of the Cleveland Clinic. The 53-year-old fitness enthusiast and his crew have an important job: nurturing inventions that emerge from several thousand scientists and doctors at the nation's top heart hospital, and guiding them through a years-long process to commercial viability, according to the Cleveland Plain Dealer.
Arterial Remodeling Technologies, a French company whose technology was developed in part by the Cleveland Clinic, has raised $8.5 million in venture capital funding to further develop its biodegradable stents.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Earlier this year, Arizona-based Carefx Corp. licensed from Clinic spin off IntellisEPM the right to market and develop so-called "dashboards" that deliver information about how a hospital is performing on a wide range of measures, from quality of care to patient outcomes to scheduling.
Updated 4:36 p.m. Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies. Perhaps most impressive, those companies — 33 in all — have attracted more than $340 million […]
Health information technology is hot at Cleveland Clinic Innovations, these days. The corporate venturing arm of the Cleveland Clinic has built operations to a crescendo in its first decade, according to Chris Coburn, executive director of the unit and the Clinic’s chief of technology commercialization. While Coburn’s unit may be better known for spinning off […]
The Cleveland Clinic is looking for tenants to occupy the Global Cardiovascular Innovation Center it's building on the southern edge of its main campus. The $19 million project at East 101st Street and Cedar Road will host wet laboratories and offices, conference rooms and informal meeting areas, artwork and sophisticated teleconferencing and audio-visual technologies when it opens, likely in May.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Autonomic is creating a small, implantable medical device to treat severe headaches, according to a news release from InterWest. It was created in 2007 through research by Clinic neurologist Dr. Ali Rezai, who remains on the company's board.
